Published on: 26 February 2026

The global rise in obesity and type 2 diabetes (T2D) has precipitated an increase in obesity-associated cancers (OAC), posing significant challenges for healthcare providers. These cancers include breast, colorectal, uterine, renal, and several others linked to metabolic dysfunction. Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have emerged as widely used oral agents for T2D treatment. Beyond their glucose-lowering effects, SGLT-2 inhibitors promote modest weight loss and demonstrate cardio-renal protective benefits. This evolving pharmacotherapy raises a critical question: do SGLT-2 inhibitors influence the risk of obesity-associated cancers in patients with T2D?

Real-World Evidence on SGLT-2 Inhibitors and Obesity-Associated Cancers

A large-scale retrospective cohort study analyzed electronic health records from the US TriNetX network, comparing individuals with T2D initiating SGLT-2 inhibitors versus those starting dipeptidyl peptidase-4 inhibitors (DPP-4i). The study excluded patients with prior cancers or those diagnosed within six months of therapy initiation to minimize bias. Propensity score matching balanced key confounders such as age, sex, BMI, HbA1c, comorbidities, and medication use, ensuring robust comparative groups.

Over a mean follow-up exceeding three years, SGLT-2 inhibitor initiation showed no statistically significant association with the composite risk of obesity-associated cancers compared to DPP-4 inhibitors. This finding held true across subgroups stratified by overweight and obesity status. These results suggest that SGLT-2 inhibitors neither increase nor decrease the overall risk of obesity-associated cancers in this population.

Site-Specific Cancer Outcomes: Renal and Thyroid Cancer Findings

Delving into individual cancer types revealed nuanced associations. Notably, SGLT-2 inhibitor use correlated with a significant reduction in renal cancer incidence. This protective effect persisted across overweight/obese subgroups and sensitivity analyses, including those accounting for treatment persistence and exclusion of confounding GLP-1 receptor agonist use.

Conversely, an increased rate of thyroid cancer was observed among SGLT-2 inhibitor users in the primary analysis. However, this association disappeared in sensitivity and subgroup analyses, indicating the need for cautious interpretation and further investigation.

Weighing the Clinical Significance of SGLT-2 Inhibitors on Overall Cancer Risk

Beyond obesity-associated cancers, the study explored all-cancer incidence. SGLT-2 inhibitors were linked to a modest yet statistically significant reduction in overall cancer rates compared to DPP-4 inhibitors. This effect appeared consistent among patients with and without overweight or obesity. Nevertheless, after excluding individuals using GLP-1 receptor agonists post-initiation, this association lost statistical significance. Consequently, while the findings hint at potential cancer risk modulation, their clinical relevance remains uncertain.

Mechanistic Insights: How SGLT-2 Inhibitors May Influence Cancer Biology

Preclinical studies offer potential explanations for observed renal cancer risk reduction. SGLT-2 inhibitors may exert organ-specific anti-cancer effects through multiple pathways. These include suppressing glucose uptake in tumor cells, inhibiting oncogenic signaling such as the Wnt/β-catenin pathway, reducing angiogenesis, impairing nucleic acid synthesis, and activating the AMPK pathway. Given the roles of hyperglycemia, hyperinsulinemia, and chronic inflammation in cancer pathogenesis among T2D patients, such mechanisms align with biological plausibility.

Practical Implications for Healthcare Professionals in Weight and Diabetes Management

For clinicians managing patients with T2D and obesity, these findings provide reassurance that initiating SGLT-2 inhibitors does not elevate obesity-associated cancer risk. The consistent renal cancer risk reduction signals a promising area for future research but should not currently drive therapeutic decisions. Ongoing vigilance remains essential, especially regarding thyroid cancer signals that warrant further validation.

Moreover, understanding that weight-neutral alternatives like DPP-4 inhibitors exhibit comparable cancer risk profiles supports individualized treatment selection based on patient comorbidities and preferences. This evidence underscores the importance of multifaceted metabolic management, including weight control, glycemic optimization, and vigilant cancer screening in high-risk populations.

Limitations and Future Directions in Cancer Risk Research with SGLT-2 Inhibitors

While this study benefits from a large, diverse cohort and rigorous confounder adjustment, its retrospective design limits causal inference. Missing lifestyle data such as smoking, diet, and physical activity may contribute residual confounding. Additionally, absence of precise medication adherence and dosing information restricts exposure assessment. The reliance on diagnostic codes, rather than histopathological confirmation, may affect outcome accuracy.

Future prospective studies and randomized controlled trials focusing on long-term cancer outcomes with SGLT-2 inhibitors are necessary. Investigations into differential effects across individual SGLT-2 agents and patient subpopulations will further clarify the clinical landscape.

Conclusion: Integrating Evidence on SGLT-2 Inhibitors and Obesity-Associated Cancer Risk

In summary, initiation of SGLT-2 inhibitors in individuals with type 2 diabetes does not significantly alter the risk of obesity-associated cancers compared to DPP-4 inhibitors. The observed renal cancer risk reduction offers intriguing mechanistic possibilities. However, modest changes in overall cancer incidence require cautious interpretation, especially considering confounding factors.

As healthcare professionals dedicated to weight and diabetes management within diverse populations, incorporating this nuanced evidence into clinical decision-making enhances patient care. Continued research will illuminate the evolving role of SGLT-2 inhibitors in cancer risk modulation, reinforcing their place in comprehensive metabolic therapy.

Source: https://doi.org/10.1111/dom.70562

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT